Detalhe da pesquisa
1.
Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).
Infect Dis Ther
; 12(12): 2691-2707, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37914983